Cartesian Therapeutics (RNAC) Other financing activities (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Other financing activities of $279000.0 for Q1 2026, up 52.46% year-over-year from $183000.0 in Q1 2025, and up 204.1% quarter-over-quarter from -$268000.0 in Q3 2025.
Cartesian Therapeutics (RNAC) Other financing activities (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Other financing activities for 10 consecutive years, with $279000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 52.46% year-over-year to $279000.0; the TTM figure through Mar 2026 stood at $96000.0 (down 99.92% YoY), while the FY2024 annual figure was $124.4 million, changed N/A from the prior year.
- Other financing activities advanced to $279000.0 in Q1 2026 per RNAC's latest filing, from -$268000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $121.6 million in Q3 2024 and bottomed at -$268000.0 in Q3 2025.
- Historically, Other financing activities has averaged $12.5 million across 4 years, with a median of $95500.0 in 2022.
- Annual changes were most pronounced in 2022 — Other financing activities surged 91.03% — and 2025, when it sank 100.22%.
- Cartesian Therapeutics' Other financing activities stood at -$46000.0 in 2022, then jumped by 264363.04% to $121.6 million in 2024, then tumbled by 100.22% to -$268000.0 in 2025, then surged by 204.1% to $279000.0 in 2026.
- Business Quant data shows RNAC's Other financing activities at $279000.0 in Q1 2026, -$268000.0 in Q3 2025, and $85000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 398,000.00 |
| Jun 30, 2026 | 398,000.00 |
| Mar 31, 2026 | 279,000.00 |
| Mar 31, 2026 | 279,000.00 |
| Sep 30, 2025 | -268,000.00 |
| Sep 30, 2025 | -268,000.00 |
| Jun 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 85,000.00 |
| Mar 31, 2025 | 183,000.00 |
| Mar 31, 2025 | 183,000.00 |
| Sep 30, 2024 | 121.56 Mn |
| Sep 30, 2024 | 121.56 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2022 | -46,000.00 |
| Dec 31, 2022 | -46,000.00 |
| Sep 30, 2022 | 29,000.00 |
| Sep 30, 2022 | 29,000.00 |
| Jun 30, 2022 | 106,000.00 |
| Jun 30, 2022 | 106,000.00 |